317358-76-2

Upstream product

• 100-39-0 benzyl bromide 
• 69455-12-5 4-benzyloxy-3-bromobenzaldehyde 
• 2973-78-6 3-bromo-4-hydroxybenzylaldehyde 
• 2315-86-8 3-bromo-4-hydroxybenzonitrile 
• 100-44-7 benzyl chloride 

Downstream Products

• 1311138-63-2 3-ethyl-4-[(phenylmethyl)oxy]benzonitrile 
• 1311137-16-2 4-{[5-(4,4-dimethyl-2,5-dioxo-1-imidazolidinyl)-2-pyridinyl]oxy}-3-ethylbenzonitrile 
• 4997-55-1 3-ethyl-4-hydroxy-benzonitrile 
• 1134197-88-8 3-{[1-(trans-1-methyl-4-{[2-(methyloxy)ethyl]oxy}cyclohexyl)-4-piperidinyl]amino}-4-[(phenylmethyl)oxy]benzonitrile 

Relevant academic research and scientific papers

Synthesis of benzyloxycyanophenylboronic esters

The synthesis of six new benzyloxycyanoboronic esters: 2-benzyloxy-6- cyanophenyl-4,4,5,5-tetramethyl-[1,3,2]-dioxaborolane (4a), 4-benzyloxy-2- cyanophenyl-4,4,5, 5-tetramethyl-[1,3,2]dioxaborolane (4b), 4-benzyloxy-3- cyanophenyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (8a), 2-benzyloxy-5- cyanophenyl-4,4,5,5-tetramethyl-[1,3,2]-dioxaborolane (8b), 3-benzyloxy-4- cyanophenyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (12a), and 2-benzyloxy-5-cyanophenyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (12b) is reported. Copyright by Walter de Gruyter Berlin Boston.

Progress toward the total synthesis of 9β-hydroxyvertine: Construction of an advanced quinolizidine intermediate

Progress toward the total synthesis of 9β-hydroxyvertine 2 is described. Our approach involves a Petasis borono-Mannich reaction to assemble a key intermediate A, securing the correct configuration at H-9 and H-10 in the final targeted molecule. Subsequen

CONDENSED HETEROCYCLIC COMPOUND

The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, t

IMIDAZOLIDINEDIONE DERIVATIVES

The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy.

COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE

Compounds of formula (I) or a salt thereof are provided: wherein R4, R5, R6, Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.